Cancer Biology Program

癌症生物学项目

• 批准号: 10627030
• 负责人: Resham Bhattacharya
• 金额: $ 5.07万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10627030
• 关键词: Adipose tissue; Advanced Malignant Neoplasm; Affect; Apoptosis; Area; Attention; BMI1 gene; Basic Science; Cachexia; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Research Project; Catchment Area; Cell Cycle; Chemoresistance; Clinical Trials; Collaborations; Colon; Community Outreach; Diagnosis; Direct Costs; Doctor of Philosophy; ERBB2 gene; Epithelial Cells; Event; Evolution; Fostering; Funding; Goals; Growth Factor; Institution; Investigation; Journals; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Mammary Neoplasms; Mediating; Molecular; Muscular Atrophy; Mutation; Neoplasm Metastasis; Normal Cell; Obesity; Oklahoma; Oncogenes; Oncogenic; Peer Review; Publications; Publishing; Reporting; Research; Research Peer Review; Role; Science; Serous; Signal Pathway; Signal Transduction; Signaling Molecule; Therapeutic; Training; Translating; Tumor Suppressor Genes; angiogenesis; cancer cell; cancer drug resistance; cancer initiation; cancer prevention; cancer therapy; cell growth; cell stroma; community engagement; insight; interest; malignant breast neoplasm; meetings; member; microbiome; neoplastic cell; pre-clinical; programs; resistance mechanism; stem-like cell; translational cancer research; tumor; tumor microenvironment; tumor progression

CANCER BIOLOGY PROGRAM: ABSTRACT The overall goal of the Cancer Biology (CB) program at the Stephenson Cancer Center (SCC) is to foster research in basic mechanisms that define normal and neoplastic cell growth to gain new insights into cancer prevention, diagnosis and treatment. CB is a new program in this CCSG application, representing an evolution of the previous Preclinical Translational Cancer Research (PTCR) program driven by a strategic reorganization of programmatic research at the SCC. Research is organized around three integrated aims that focus on 1) cancer cell signaling pathways, 2) tumor microenvironment and 3) mechanisms of chemoresistance. Specific attention is placed on conducting basic mechanisms research related to Community Outreach and Engagement (COE)-identified priority cancers that affect Oklahoma (the SCC catchment area). Program members bring a diverse range of transdisciplinary expertise in basic cancer mechanisms, including: the functions of oncogenes and tumor suppressor genes; regulators of cell cycle and apoptosis; regulators of angiogenesis and metastasis; and aberrant signaling that leads to chemoresistance. The CB program seeks to channel these transdisciplinary interests in a collaborative, team-based approach. Focused interactions for members have helped foster collaboration and advance CB research. During the reporting period, the CB program conducted 135 interactive activities, including meetings, seminars, and training events. The CB program is led by Min Li, PhD and Resham Bhattacharya, PhD, who have complementary expertise in investigating basic mechanisms of cancer (Li) and translating discoveries into clinical trials (Bhattacharya). In 2021, the CB program had 39 total members (23 full, 16 associate), representing 11 different academic departments. Total peer-reviewed research funding was $6.38M, of which $2.15M was from NCI (annual, direct cost). More than a third (34%) of total peer-reviewed funding was from NCI, highlighting the cancer focus of this basic science-oriented program. Total research funding was $7.29M, with 58 active cancer-focused projects. CB members published 439 articles in peer-reviewed journals over the past five years. Of these, 24% were intra-programmatic and an exceptional 41% were inter-programmatic, underscoring the high degree of collaboration, both within the program and with members in the SCC’s Cancer Therapeutics (CT) and Cancer Prevention and Control (CPC) programs. Multi-institutional publications (n=297) account for 68% of the total. The number and percentage of high-impact publications increased over the period, from 12 (14%) in 2017 to 24 (24%) in 2021, averaging 18% for the period. This significant increase in high-impact publications highlights the quality of science being conducted by CB members.

癌症生物学计划：摘要 斯蒂芬森癌症中心（SCC）的癌症生物学（CB）计划的总体目标是促进 基本机制的研究，这些机制定义了正常和肿瘤细胞生长，以获得对癌症的新见解 预防，诊断和治疗。 CB是此CCSG应用程序中的新程序，代表进化 由战略重组驱动的先前临床前转化癌研究（PTCR）计划 SCC的程序化研究。研究围绕着三个关注1的综合目的组织1） 癌细胞信号通路，2）肿瘤微环境和3）化学耐药机制。具体的 注意进行与社区外展有关的基本机制研究和 参与（COE）识别的优先癌症癌症（SCC集水区）​​。程序 成员在基本癌症机制方面带来了潜水员的跨学科专业知识，包括： 癌基因和肿瘤抑制基因的功能；细胞周期和凋亡的调节剂；监管机构 血管生成和转移；以及导致化学抗性的异常信号传导。 CB计划试图 以协作，基于团队的方法来引导这些跨学科利益。集中互动 成员帮助促进了协作并推进了CB研究。在报告期间，CB 计划进行了135次互动活动，包括会议，半手和培训活动。 CB 计划由Min Li，PhD和Resham Bhattacharya博士领导，他们拥有完整的专业知识 研究癌症的基本机制（LI），并将发现转化为临床试验（Bhattacharya）。 在2021年，CB计划共有39个成员（23个完整，16名合伙人），代表11个不同的学术 部门。同行评审的总研究资金为638万美元，其中215万美元来自NCI（年度， 直接费用）。超过三分之一（34％）的总同行评审资金来自NCI，突出了癌症的重点 这个以科学为基础的计划。总研究资金为729万美元，有58个活跃的癌症为中心 项目。在过去的五年中，CB成员在同行评审期刊上发表了439篇文章。其中24％ 是截面性的，异常的41％是截面的，强调了高度的高度 在计划中以及与SCC癌症治疗学（CT）和癌症中的成员中的合作 预防和控制（CPC）计划。多机构出版物（n = 297）占总数的68％。 在此期间，高影响力出版物的数量和百分比增加了，从2017年的12个（14％）到 2021年为24（24％），该时期平均18％。高影响力出版物的重大增长突出显示 CB成员进行的科学质量。